Eli Lilly and Company moved higher in afternoon trading after posting a quarterly report that outpaced Wall Street expectations by a wide margin. The company reported Q2 2026 revenue of $22.97 billion, a 48% increase from the year-ago period, and adjusted earnings per share of $8.38, both results comfortably above consensus estimates around $20.6 billion for revenue.
Management also raised its full-year 2026 revenue outlook to a range of $85 billion to $87 billion, up from the prior range of $82 billion to $85 billion. The guidance increase signals management confidence in the durability of the company’s current growth drivers.
What drove the quarter
The quarter’s gains were concentrated in Lilly’s GLP-1 franchise. Mounjaro produced $9.9 billion in sales, a 91% year-over-year increase, while Zepbound contributed $4.9 billion. Combined, those two products made up roughly 65% of total quarterly revenue.
The period also included the first full quarter of sales for Foundayo, Lilly’s newly approved oral obesity treatment, which added $98 million to revenue. In addition to commercial performance, the company received a regulatory boost when the FDA granted Breakthrough Therapy designation to olomorasib, Lilly’s oncology candidate for advanced pancreatic cancer.
CEO David Ricks highlighted another favorable development outside the company’s direct results, noting that Medicare’s new obesity drug coverage, which began earlier in July, is "off to a strong start." That reimbursement shift is a material contextual factor for products in the obesity treatment category.
Market reaction and competitive context
Shares moved notably higher on the news, with the stock rallying 3.9% in afternoon trading. Intraday market data also reflected gains of about 4.22% at points during the session, as investors weighed the combination of a sizable top-line beat, an upgraded outlook, and pipeline progress.
The broader market provided little lift on the day - the S&P 500 was essentially flat, the Dow Jones was modestly higher, and the Nasdaq traded in negative territory. Rival Novo Nordisk reported results a day earlier and saw its shares decline after oral Wegovy sales disappointed, a dynamic that amplified investor focus on Lilly’s competitive position within the GLP-1 space.
Bottom line
Investors responded to the convergence of stronger-than-expected financials, a raised revenue target, regulatory progress on an oncology asset, and improving reimbursement for obesity drugs. Those elements combined to lift sentiment toward Lilly shares during the trading session and pushed the equity toward the upper end of its daily range, approaching its 52-week high.